Poster – Novel Image Analysis And IHC Advances For NASH
Global prevalence of non-alcoholic fatty liver disease (NAFLD) is 25.24% in 2016, a percentage that has rapidly increased over the past decade.
There exist two types of NAFLD, non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Both Masson’s Trichrome Analysis CD45/ CD138/ Adipophilin IHC subtypes are associated with lipid accumulation in the liver, the latter being more severe with inflammatory cell infiltration, fibrosis and subsequent hepatocyte damage and impaired organ function.
The current gold standard for NAFLD diagnosis is liver biopsies evaluated by experienced pathologists who assign scores for several features (fibrosis, steatosis, inflammation and ballooning). However, documented inter-pathologist variability in scoring and semi-quantitative nature of the scoring system itself highlight the need for new methods to ensure the unbiased and consistent assessment of disease.
Our colleague Maroua Tliba has presented a poster on this during EASL 2023. Discover everything here by downloading the poster.
Poster – Novel Image Analysis And IHC Advances For NASH
Presentation – Automatization Of Immunohistochemistry Data Analysis For Protocol Validation
This presentation was given by Marie Gerus-Durand, Principal Scientist & Validation Engineer at Cerba Research Montpellier at the JMP Discovery Summit Europe.
Cerba Research is a global company providing high-quality, specialized analytical and diagnostic solutions for clinical trials. Cerba Research Montpellier develops customized immunohistochemistry protocols to detect the expression of selected targets on patients’ tissue sections.
To be used in clinical trials, these protocols must meet the regulatory agencies’ criteria to ensure that the protocol will allow consistent results on precious patients’ samples. With the diversity of parameters evaluated and the types of evaluation possible in implementing these custom protocols, automating data analysis became a need.
Thanks to various JMP® tools, we have developed an automated analysis that saves time and homogenizes protocol performance reports by including statistical and graphical data in a Dashboard. This process, submitted as JMP Add-in, has been incorporated into our user workflows, thus facilitating our procedures.
Case Study – A Blood-based Biomarker Panel For Non-invasive Diagnosis Of Non-alcoholic Steatohepatitis: A Multi-centre Prospective And Validation Study
A late-stage biopharmaceutical company dedicated to metabolic and chronic liver diseases is developing an in vitro diagnostic (IVD) test for NASH at-risk patients. The test integrates four independent biomarkers – miR-34a-5p, A2M, YKL-40, and HbA1c. The output is a 0-10 score with threshold values, identifying patients with low risk or high risk of developing NASH.
The main objective of this study is to evaluate the physiological stability of these biomarkers between the fed and fasting state in patients with the target condition (NAFLD) over a 30-day period.
Discover how our team of experts helped this biopharmaceutical company to reach its goals
Case Study – A Blood-based Biomarker Panel For Non-Invasive Diagnosis Of Non-alcoholic Steatohepatitis: A Multi-centre Prospective And Validation Study
Poster – Non-Invasive Serum Lipidomic Approach To Discriminate Non-Alcoholic Steatohepatitis (NASH) In Multiethnic Patients With Type 2 Diabetes Mellitus
Despite the growing prevalence of NASH, there are currently no approved treatments for the disease beyond liver transplant. The constellation of risk factors for NASH has generated a multitude of targets and there is an obvious need to bring promising treatments through clinical trials and to patients quickly.
Publication – Non-Invasive Serum Lipidomic Approach To Discriminate Non-Alcoholic Steatohepatitis In Multiethnic Patients With Type 2 Diabetes Mellitus
Experience the fascinating world of histopathology through the eyes of our skilled scientists.
Immunohistochemistry (IHC) biomarkers are crucial in clinical development. These tissue biomarkers assist in diagnosis confirmation, patient selection, and mechanistic evaluation.
Our team of IHC experts offers personalized consultations, providing flexible and efficient solutions tailored to your specific needs. We are committed to delivering timely, cost-effective results to achieve your clinical and commercial objectives.
Why Choose Cerba Research For IHC Services?
Expertise: Our experienced team brings deep scientific knowledge and practical insights.
Customization: Solutions tailored to fit your unique clinical and commercial needs.
Efficiency: Flexible, timely, and cost-effective services to streamline your projects.
Innovation: Cutting-edge techniques to ensure the highest quality results.
Download our digital book to explore the art of histopathology and learn how Cerba Research can support your clinical research goals.
Webinar – Advantages And Versatility Of Flow Cytometry Considerations For Clinical Trial Speciality Lab Outsourcing
It is now clear that the therapeutic future lies in biomarkers through the development of immunotherapies and companion diagnostics. Among the techniques of biomarker analysis, there is Flowcytometry, which allows for precise analysis of liquid samples, but not only.
Validation test development for specific biomarkers is a prerequisite for a successful application in translational research, preclinical and clinical phases. The advantages and disadvantages of this technique, the samples, and the conditions of use: Cerba Research will open the doors of its worldwide laboratories for an hour. To answer all your questions about one of the leading techniques of analysis for the development of innovative treatments, our experts will share their knowledge and experience.
Nithianandan Selliah, Ph.D., Global Head of Flow Cytometry at Cerba Research
Nithianandan obtained his PhD in Immunology and started to work on HIV research. After more than 10 years of HIV research, he joined a biotech company to work on biomarker discovery for autoimmune diseases. His interest in Flow cytometry at the biotech company led him to join global CRO to work on assay development and validation in Flow cytometry for global clinical trials. He joined Cerba Research to continue to work on his passion for Flow cytometry in clinical trial and takes on new challenges to build the best Flow cytometry service to the clients.
He is working with exceptional scientific teams in the US and Belgium to bring on new assays for various therapeutic indications, including Immuno-oncology and autoimmune diseases.
Ishita Modi, Director, Scientific Customer Solutions at Cerba Research
A microbiologist by education, Ishita finished her studies at Gujarat University in India and moved on to start her career in the United States. She has more than 15 years of experience in the clinical and diagnostic research industry. Her expertise is in building a strong foundation of clinical operations and clinical research with a commitment to meeting client’s scientific needs to help advance medicine. Ishita has worked at CRO/Central Lab as well as at some of the leading clinical diagnostic labs in the region. Her scientific expertise includes infectious diseases and genetics, and gained extensive experience in microbiology, virology, and molecular biology. Ishita is a New York State-certified Medical Technologist and also a certified IRB (Institutional Review Board) professional. Her experience over the years has made her very strong in all aspects of clinical research and regulatory requirements. She has a passion for advancing science and making a difference in the future of healthcare.
Webinar – Advantages and Versatility of Flow Cytometry Considerations for Clinical trial Speciality Lab Outsourcing
Reach out to our experts to see how we can help advance your clinical trial
Resource Library
